David A Mankoff

List of Publications by Year
in descending order

167 papers	9,305 citations	26630 56 h-index	42399 92 g-index
171 all docs	171 docs citations	171 times ranked	10020 citing authors

#	Article	IF	Citations
1	Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 2785-2808.	7.0	582
2	Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of Nuclear Medicine, 2006, 47, 1059-66.	5.0	522
3	Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2793-2799.	1.6	357
4	Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia, 2019, 21, 1-16.	5.3	316
5	Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer. Journal of Histochemistry and Cytochemistry, 1997, 45, 1559-1565.	2.5	282
6	Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics, 2005, 77, 503-514.	4.7	243
7	Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol. Journal of Nuclear Medicine, 2008, 49, 367-374.	5.0	232
8	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985.	7.0	219
9	Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. Journal of Nuclear Medicine, 2002, 43, 500-9.	5.0	183
10	Cancer biomarkers: a systems approach. Nature Biotechnology, 2006, 24, 905-908.	17.5	176
11	PET/CT imaging in cancer: Current applications and future directions. Cancer, 2014, 120, 3433-3445.	4.1	170
12	Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology, 2017, 285, 358-375.	7.3	159
13	Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. Journal of Nuclear Medicine, 2014, 55, 1106-1111.	5.0	156
14	Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond. Clinical Cancer Research, 2007, 13, 3460-3469.	7.0	154
15	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	10.7	153
16	Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. Journal of Nuclear Medicine, 2003, 44, 1806-14.	5.0	151
17	PET imaging of cellular proliferation. Radiologic Clinics of North America, 2005, 43, 153-167.	1.8	144
18	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4449-4457.	1.6	142

#	Article	IF	Citations
19	Tumor Receptor Imaging. Journal of Nuclear Medicine, 2008, 49, 149S-163S.	5.0	139
20	A definition of molecular imaging. Journal of Nuclear Medicine, 2007, 48, 18N, 21N.	5.0	138
21	^{18}F-FDG PET/CT for Staging and Restaging of Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 17S-26S.	5.0	135
22	Use of Serial FDG PET to Measure the Response of Bone-Dominant Breast Cancer to Therapy. Academic Radiology, 2002, 9, 913-921.	2.5	132
23	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 4799-4805.	7.0	120
24	The Impact of Positron Emission Tomography with ^{18}F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.4	113
25	Bacterial infection imaging with [^{18}F]fluoropropyl-trimethoprim. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8372-8377.	7.1	111
26	Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. Journal of Nuclear Medicine, 2005, 46, 274-82.	5.0	108
27	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer, 1999, 85, 2410-2423.	4.1	107
28	Quantitative Imaging in Cancer Clinical Trials. Clinical Cancer Research, 2016, 22, 284-290.	7.0	106
29	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Research, 2016, 76, 5933-5944.	0.9	105
30	PennPET Explorer: Human Imaging on a Whole-Body Imager. Journal of Nuclear Medicine, 2020, 61, 144-151.	5.0	102
31	Internal Mammary Lymph Node Drainage Patterns in Patients With Breast Cancer Documented by Breast Lymphoscintigraphy. Annals of Surgical Oncology, 2001, 8, 234-240.	1.5	101
32	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. Journal of Clinical Investigation, 2018, 128, 2116-2126.	8.2	100
33	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. Clinical Cancer Research, 2016, 22, 5079-5086.	7.0	99
34	Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment, 2007, 105, 87-94.	2.5	97
35	Impact of Time-of-Flight PET on Whole-Body Oncologic Studies: A Human Observer Lesion Detection and Localization Study. Journal of Nuclear Medicine, 2011, 52, 712-719.	5.0	94
36	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. Clinical Cancer Research, 2011, 17, 2400-2409.	7.0	94

#	Article	IF	Citations
37	18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. Journal of Nuclear Medicine, 2004, 45, 1829-37.	5.0	92
38	SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. Journal of Nuclear Medicine, 2003, 44, 1044-50.	5.0	91
39	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clinical Cancer Research, 2017, 23, 407-415.	7.0	88
40	^{18}F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. Journal of Nuclear Medicine, 2016, 57, 1269-1275.	5.0	83
41	Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-Fluorestradiol (FES). Nuclear Medicine and Biology, 1997, 24, 341-348.	0.6	80
42	A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Molecular Imaging and Biology, 2014, 16, 431-440.	2.6	80
43	ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology, 2016, 13, R45-R49.	1.8	80
44	C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases. Clinical Nuclear Medicine, 2011, 36, 192-198.	1.3	76
45	[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. Cancer Research, 2017, 77, 1476-1484.	0.9	75
46	A Phase II Study of 3′-Deoxy-3′-^{18}F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Journal of Nuclear Medicine, 2015, 56, 1681-1689.	5.0	73
47	Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy1. Academic Radiology, 2004, 11, 1115-1124.	2.5	69
48	18F-Fluoroestradiol. Seminars in Nuclear Medicine, 2007, 37, 470-476.	4.6	68
49	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. Journal of Nuclear Medicine, 2020, 61, 263S-272S.	5.0	67
50	Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by ^{18}F-Fluoroestradiol PET. Journal of Nuclear Medicine, 2011, 52, 1541-1549.	5.0	65
51	Molecular Imaging Biomarkers for Oncology Clinical Trials. Journal of Nuclear Medicine, 2014, 55, 525-528.	5.0	63
52	Metabolic Imaging of Glutamine in Cancer. Journal of Nuclear Medicine, 2017, 58, 533-537.	5.0	63
53	Making Molecular Imaging a Clinical Tool for Precision Oncology. JAMA Oncology, 2017, 3, 695.	7.1	63
54	Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nuclear Medicine and Biology, 2011, 38, 969-978.	0.6	62

#	Article	IF	Citations
55	Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF. Journal of Nuclear Medicine, 2007, 48, 920-925.	5.0	61
56	18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 983-993.	6.4	58
57	Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines. Seminars in Nuclear Medicine, 2016, 46, 147-164.	4.6	58
58	[Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nuclear Medicine and Biology, 2002, 29, 719-727.	0.6	54
59	Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies. Journal of Nuclear Medicine, 2018, 59, 1340-1349.	5.0	50
60	Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer, 2005, 103, 680-688.	4.1	43
61	Prospective Study of Serial ^{18}F-FDG PET and ^{18}F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 1823-1830.	5.0	41
62	Development of Companion Diagnostics. Seminars in Nuclear Medicine, 2016, 46, 47-56.	4.6	40
63	Molecular Imaging Research in the Outcomes Era. Academic Radiology, 2007, 14, 398-405.	2.5	39
64	Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metabolism and Disposition, 2015, 43, 1795-1804.	3.3	37
65	Quantitative PET in the 2020s: a roadmap. Physics in Medicine and Biology, 2021, 66, 06RM01.	3.0	36
66	18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions. Journal of Nuclear Medicine, 2015, 56, 1223-1228.	5.0	33
67	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. Journal of Biomedical Optics, 2018, 24, 1.	2.6	32
68	The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2â€"Response to Therapy, Other Indications, and Future Directions. Journal of Nuclear Medicine, 2009, 50, 738-748.	5.0	30
69	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1219-1235.	0.8	30
70	[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 94-101.	1.0	30
71	ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. Journal of the American College of Radiology, 2014, 11, 1160-1168.	1.8	29
72	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Research, 2012, 2, 34.	2.5	27

#	Article	IF	Citations
73	Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim. Molecular Therapy, 2017, 25, 120-126.	8.2	27
74	Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clinical Cancer Research, 2019, 25, 3063-3073.	7.0	27
75	The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomes. PLoS ONE, 2020, 15, e0228931.	2.5	27
76	Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer. JAMA Oncology, 2020, 6, 921.	7.1	26
77	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. Cancer Letters, 2017, 387, 25-31.	7.2	24
78	Breast Cancer[18]F-ISO-1 Uptake as a Marker of Proliferation Status. Journal of Nuclear Medicine, 2020, 61, 665-670.	5.0	24
79	Role of PET quantitation in the monitoring of cancer response to treatment: review of approaches and human clinical trials. Clinical and Translational Imaging, 2014, 2, 295-303.	2.1	23
80	Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. , 2016, 4, 27.		23
81	Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. Journal of Nuclear Medicine, 2016, 57, 226-230.	5.0	21
82	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS ONE, 2018, 13, e0198548.	2.5	21
83	Fulvestrant for the Treatment of Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2019, 16, 1456-1459.	3.2	21
84	Test–Retest Reproducibility of ^{18}F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. Journal of Nuclear Medicine, 2019, 60, 608-614.	5.0	21
85	^{18}F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2ˆ Metastatic Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 184-190.	5.0	20
86	How Imaging Can Impact Clinical Trial Design. Cancer Journal (Sudbury, Mass), 2015, 21, 218-224.	2.0	19
87	Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 5521-5526.	0.9	19
88	Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer. PET Clinics, 2006, 1, 71-81.	3.0	18
89	The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic. Nuclear Medicine and Biology, 2016, 43, 35-41.	0.6	18
90	Preoperative MRI Improves Prediction of Extensive Occult Axillary Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Lymph Node Biopsy. Academic Radiology, 2014, 21, 92-98.	2.5	17

#	ARTICLE	IF	CITATIONS
91	ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology, 2016, 13, e31-e42.	1.8	17
92	Assessment of the Prognostic Value of Radiomic Features in 18F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial. Tomography, 2020, 6, 14-22.	1.8	17
93	How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. JAMA Oncology, 2015, 1, 421.	7.1	16
94	Molecular Imaging and Precision Medicine in Breast Cancer. PET Clinics, 2017, 12, 39-51.	3.0	16
95	Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology. Current Pathobiology Reports, 2019, 7, 97-108.	3.4	15
96	Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism. Journal of Nuclear Medicine, 2020, 62, jnumed.120.250977.	5.0	15
97	Challenges in clinical studies with multiple imaging probes. Nuclear Medicine and Biology, 2007, 34, 879-885.	0.6	14
98	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1178-1187.	4.4	14
99	ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. Journal of the American College of Radiology, 2016, 13, e43-e52.	1.8	13
100	Quantifying Bias and Precision of Kinetic Parameter Estimation on the PennPET Explorer, a Long Axial Field-of-View Scanner. IEEE Transactions on Radiation and Plasma Medical Sciences, 2020, 4, 735-749.	3.7	13
101	Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2021, 4, e212274.	5.9	13
102	Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology. Journal of Nuclear Medicine, 2022, 63, 342-352.	5.0	13
103	Nuclear Medicine Training: What Now?. Journal of Nuclear Medicine, 2017, 58, 1536-1538.	5.0	12
104	Transitioning From Radiology Training to Academic Faculty: The Importance of Mentorship. Current Problems in Diagnostic Radiology, 2020, 49, 219-223.	1.4	12
105	Effect of 18F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. Tomography, 2015, 1, 53-60.	1.8	12
106	A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. Translational Oncology, 2014, 7, 138-146.	3.7	11
107	Radiopharmaceutical Chemistry and Drug Development—What's Changed?. Seminars in Radiation Oncology, 2021, 31, 3-11.	2.2	11
108	Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1—Targeted ^{18}F-Fluorthanatrace PET Images of Ovarian Cancer. Journal of Nuclear Medicine, 2022, 63, 44-50.	5.0	11

#	Article	IF	Citations
109	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. Breast Cancer Research, 2021, 23, 88.	5.0	11
110	Are we ready for dedicated breast imaging approaches?. Journal of Nuclear Medicine, 2003, 44, 594-5.	5.0	11
111	Choosing a single target as a biomarker or therapeutic using radioactive probes. Nuclear Medicine and Biology, 2015, 42, 421-425.	0.6	10
112	Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment. Journal of Nuclear Medicine, 2016, 57, 69S-74S.	5.0	10
113	A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. PLoS ONE, 2017, 12, e0178325.	2.5	10
114	Performance of Positron Imaging Systems as a Function of Energy Threshold and Shielding Depth. IEEE Transactions on Medical Imaging, 1984, 3, 18-24.	8.9	9
115	ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice. Journal of Nuclear Medicine, 2011, 52, 994-997.	5.0	9
116	Imaging Tumor Proliferation in Breast Cancer. PET Clinics, 2018, 13, 445-457.	3.0	9
117	Impact of Early Radiology Research Experiences on Medical Student Perceptions of Radiology and Research. Current Problems in Diagnostic Radiology, 2019, 48, 423-426.	1.4	9
118	Imaging endpoints of intracranial atherosclerosis using vessel wall MR imaging: a systematic review. Neuroradiology, 2021, 63, 847-856.	2.2	9
119	The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. Journal of Nuclear Medicine, 2015, 56, 1133-1134.	5.0	8
120	Analysis of Four-Dimensional Data for Total Body PET Imaging. PET Clinics, 2021, 16, 55-64.	3.0	8
121	PET imaging for assessing tumor response to therapy. Journal of Surgical Oncology, 2018, 118, 362-373.	1.7	7
122	The contribution of physics to Nuclear Medicine: physicians' perspective on future directions. EJNMMI Physics, 2014, 1, 5.	2.7	6
123	Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.‐Based Neuroendocrine Tumor Cohort. Oncologist, 2020, 25, 572-578.	3.7	6
124	Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3990-4001.	6.4	6
125	Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies. Journal of Nuclear Medicine, 2021, 62, 1672-1676.	5.0	6
126	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography. Cancer, 1999, 85, 2410-2423.	4.1	6

#	Article	IF	Citations
127	Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer. Oncology, 2014, 28, 424-30.	0.5	6
128	Novel applications of molecular imaging to guide breast cancer therapy. Cancer Imaging, 2022, 22, .	2.8	6
129	Proliferation Imaging to Measure Early Cancer Response to Targeted Therapy. Clinical Cancer Research, 2008, 14, 7159-7160.	7.0	5
130	Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 5.	3.9	5
131	Analysis of Routine Computed Tomographic Scans With Radiomics and Machine Learning. JAMA Oncology, 2022, , .	7.1	5
132	Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions. Journal of Nuclear Medicine, 2022, 63, 514-521.	5.0	5
133	Total Body PET â€" Will it Change Science and Practice?. Journal of Nuclear Medicine, 2022, , jnumed.121.263481.	5.0	5
134	18F-Fluoroestradiol (FES) PET/CT: review of current practice and future directions. Clinical and Translational Imaging, 2022, 10, 331-341.	2.1	5
135	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	3.7	4
136	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography, 2021, 7, 139-152.	1.8	4
137	Quantitation of multiple injection dynamic PET scans: an investigation of the benefits of pooling data from separate scans when mapping kinetics. Physics in Medicine and Biology, 2021, 66, 135010.	3.0	4
138	Internal Mammary Lymph Node Drainage Patterns in Patients With Breast Cancer Documented by Breast Lymphoscintigraphy. Annals of Surgical Oncology, 2001, 8, 234-240.	1.5	4
139	PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging. Radiology, 2021, , 212098.	7.3	4
140	Introduction and Overview. Journal of Nuclear Medicine, 2016, 57, 1S-2S.	5.0	3
141	PET oestrogen receptor imaging: ready for the clinic?. Lancet Oncology, The, 2019, 20, 467-469.	10.7	3
142	Transitioning from Radiology Training to Academic Faculty: Defining Your Role and Interests. Current Problems in Diagnostic Radiology, 2020, 49, 227-230.	1.4	3
143	A Bright Future for Nuclear Endocrinology. Journal of Nuclear Medicine, 2021, 62, 1S-2S.	5.0	3
144	Imaging Studies in Anticancer Drug Development. , 2011, , 275-302.		3

#	Article	IF	Citations
145	The Development of ¹⁸F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. Radiology Imaging Cancer, 2022, 4, e210070.	1.6	3
146	The role of PET in the management of brain tumors. , 0, , 8-20.		3
147	Multi-Frame Data Acquisition for PET Camera Using an On-Line Microprocessor-Based System. IEEE Transactions on Nuclear Science, 1986, 33, 443-445.	2.0	2
148	ACR Appropriateness CriteriaÂ® Stage I Breast Carcinoma. Journal of the American College of Radiology, 2016, 13, e53-e57.	1.8	2
149	Clinical overview of the current state and future applications of positron emission tomography in bone and soft tissue sarcoma. Clinical and Translational Imaging, 2017, 5, 343-358.	2.1	2
150	An Illustration of the Use of Model-Based Bootstrapping for Evaluation of Uncertainty in Kinetic Information Derived from Dynamic PET. , 2019, , .		2
151	Update on Quantitative Imaging for Predicting and Assessing Response in Oncology. Seminars in Nuclear Medicine, 2020, 50, 505-517.	4.6	2
152	PET Molecular Imaging as a Tool for Precision Oncology. Radiology, 2020, 296, 379-380.	7.3	2
153	Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer.. Journal of Clinical Oncology, 2016, 34, e12039-e12039.	1.6	2
154	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. Tomography, 2020, 6, 60-64.	1.8	2
155	Evaluating the Impact of New Imaging Tests: Promises and Pitfalls. Journal of the National Cancer Institute, 2012, 104, 1858-1859.	6.3	1
156	A PET Glutamate Analogue to Measure Cancer Cell Redox State and Oxidative Stress: Promise and Paradox. Cancer Research, 2019, 79, 701-703.	0.9	1
157	PET/MRI for Primary Breast Cancer: A Match Made Better by PET Quantification?. Radiology Imaging Cancer, 2021, 3, e200150.	1.6	1
158	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. , 1999, 85, 2410.		1
159	Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11569-11569.	1.6	1
160	18F-FDG-PET/CT in Breast and Gynecologic Cancer. , 2020, , 627-650.		1
161	Improving lesion detectability in low uptake 18 F-FDG breast cancer by optimizing PET imaging time. , 2014, , .		0
162	A Simple Evaluation of the Benefit of Combined Kinetic Analysis of Multiple Injection Dynamic PET Scans. , 2019, , .		0

#	Article	IF	Citations
163	An exploration of the prognostic utility of shortened dynamic imaging protocols for PET-FDG scans. , 2019, , .		0
164	PET Imaging in Cancer Clinical Trials. , 2021, , 1503-1516.		0
165	Myocardial perfusion PET imaging to evaluate coronary microvascular dysfunction in men with prostate cancer receiving androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 211-211.	1.6	0
166	Development of Radiographic Contrast Agents for Diagnostic Imaging. , 0, , .		0
167	Clinical Translation and Adaption. , 2021, , 1-16.		0